

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-63. (Canceled)

64. (New) A method for identifying a chemosensitizing compound that reverses non P-gp/non MRP multiple drug resistance in cancer cells which exhibit non P-gp/nom MRP drug resistance phenotype which comprises:

- a. contacting said cells with a test compound and a chemotherapeutic agent to which cancer cells are resistant and measuring cancer cell survival;
- b. contacting said cells with a chemotherapeutic agent to which cancer cells are resistant and measuring cancer cell survival;
- c. comparing cancer cell survival of step a to step b; and
- d. identifying a test compound which shows an increase in cancer cell death in step a, which indicates that said test compound is a chemosensitizing compound.

65. (New) A method according to claim 64 wherein the chemotherapeutic agent is selected from mitoxantrone, doxorubicin, and topotecan.

66. (New) A method for identifying a chemosensitizing compound that reverses BCRP-mediated multiple drug resistance in cancer cells which exhibit BCRP-mediated multiple drug resistance which comprises:

- a. contacting said cells with a test compound and a chemotherapeutic agent to which cancer cells are resistant and measuring cancer cell survival;
- b. contacting said cells with a chemotherapeutic agent to which cancer cells are resistant and measuring cancer cell survival;
- c. comparing cancer cell survival of step a to step b; and
- d. identifying a test compound which shows an increase in cancer cell death in step a, which indicates that said test compound is a chemosensitizing compound.

67. (New) A method according to claim 66 wherein the chemotherapeutic agent is selected from mitoxantrone, doxorubicin, and topotecan.

68. (New) A method according to claim 64 wherein the increase in cancer cell death is about 22% or above.

69. (New) A method according to claim 66 wherein the increase in cancer cell death is about 22% or above.